Drug Price Trends for ATIVAN

Average Pharmacy Cost for ATIVAN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ATIVAN 1 MG TABLET	00187-0064-01	47.15987	EACH	2025-09-17
ATIVAN 1 MG TABLET	00187-0064-10	47.15987	EACH	2025-09-17
ATIVAN 0.5 MG TABLET	00187-0063-01	35.34227	EACH	2025-09-17
ATIVAN 1 MG TABLET	00187-0064-01	47.16517	EACH	2025-08-20

Best Wholesale Price for ATIVAN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
ATIVAN 4MG/ML INJ	Hikma Pharmaceuticals USA Inc.	00641-6002-10	10X10ML	132.69			2024-01-01 - 2026-08-14	Big4
ATIVAN 2MG/ML INJ	Hikma Pharmaceuticals USA Inc.	00641-6001-25	25X1ML	40.84			2024-01-01 - 2026-08-14	FSS
ATIVAN 4MG/ML INJ	Hikma Pharmaceuticals USA Inc.	00641-6003-25	25X1ML	56.66			2024-01-01 - 2026-08-14	FSS
ATIVAN 2MG/ML INJ MDV	Hikma Pharmaceuticals USA Inc.	00641-6000-10	10X10ML	151.57			2024-01-01 - 2026-08-14	FSS

ATIVAN (Lorazepam) Market Analysis and Price Projections

Last updated: February 19, 2026

This report analyzes the global market for ATIVAN (lorazepam), a benzodiazepine medication used to treat anxiety and insomnia. It examines patent exclusivity, generic competition, market trends, and projects future pricing based on these factors.

What is ATIVAN (Lorazepam)?

ATIVAN is a prescription medication belonging to the benzodiazepine class of drugs. Its active pharmaceutical ingredient is lorazepam. It functions as a central nervous system depressant, enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA), which reduces nerve activity in the brain. This action results in sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant effects.

ATIVAN is indicated for the short-term management of anxiety disorders, relief of symptoms of anxiety associated with depressive symptoms, and for the management of insomnia characterized by difficulty in falling or staying asleep. It is also used as a preanesthetic medication to induce sedation and reduce anxiety and recall prior to medical procedures.

Key therapeutic areas include:

• Generalized Anxiety Disorder (GAD)
• Panic Disorder
• Anxiety due to depression
• Insomnia

ATIVAN is available in oral tablet and injectable formulations. Oral dosages typically range from 0.5 mg to 10 mg per day, while injectable formulations are administered intramuscularly or intravenously.

Patent Exclusivity and Generic Competition

The original patents for lorazepam, held by American Home Products (now part of Pfizer), expired decades ago. The U.S. patent for lorazepam expired in 1987. [1] This long period of patent expiry has allowed for the widespread development and marketing of generic versions of lorazepam.

The market for lorazepam is therefore dominated by generic manufacturers. Several companies hold Abbreviated New Drug Applications (ANDAs) approved by the U.S. Food and Drug Administration (FDA) for lorazepam tablets and injections.

Key generic manufacturers and their market presence include:

• Teva Pharmaceuticals: A major player in the generic drug market, Teva offers a range of lorazepam strengths.
• Par Pharmaceutical: Another significant generic supplier, Par provides both oral and injectable lorazepam.
• Sun Pharmaceutical Industries: Sun Pharma has a substantial global generic portfolio, including lorazepam.
• Mylan N.V. (now Viatris): Viatris is a prominent manufacturer and distributor of generic medications, including lorazepam.
• Amneal Pharmaceuticals: Amneal offers various generic formulations of lorazepam.

The availability of multiple generic versions has led to significant price competition. The brand name ATIVAN, manufactured by Pfizer, continues to hold a market share, primarily through physician preference, established patient familiarity, and some specialized formulary agreements. However, its market dominance is limited by the cost-effectiveness of generic alternatives.

Market Size and Trends

The global market for anxiolytics and sedatives, which includes lorazepam, is substantial and driven by the prevalence of anxiety disorders and sleep disturbances worldwide. While specific market size data for lorazepam alone is not consistently separated from broader therapeutic class reports, the overall benzodiazepine market provides a proxy.

The global anxiolytics market was valued at approximately USD 4.5 billion in 2022 and is projected to reach USD 6.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.2% during the forecast period. [2] Lorazepam, being a widely prescribed and cost-effective option, captures a significant portion of this market segment, particularly in the generic space.

Key market trends influencing lorazepam demand include:

• Rising Prevalence of Anxiety Disorders: Global increases in reported anxiety disorders, exacerbated by socio-economic stressors and public health crises, directly translate to higher demand for anxiolytic medications. The World Health Organization (WHO) estimates that nearly 300 million people globally suffer from anxiety disorders. [3]
• Aging Population: The elderly population is more susceptible to anxiety and sleep disorders, contributing to sustained demand for medications like lorazepam.
• Cost-Effectiveness: In healthcare systems prioritizing cost containment, generic lorazepam offers a highly attractive treatment option compared to newer, branded anxiolytics or non-pharmacological interventions, especially for long-term management where permitted.
• Awareness and Diagnosis: Increased public and medical awareness of mental health conditions leads to earlier diagnosis and treatment, expanding the patient pool.
• Physician Prescribing Habits: While newer classes of anxiolytics exist (e.g., SSRIs, SNRIs), benzodiazepines like lorazepam remain a first-line or adjunctive treatment for acute anxiety and insomnia due to their rapid onset of action.
• Genericization of Newer Anxiolytics: As newer anxiolytic medications lose patent protection, they also enter the generic market, intensifying competition and potentially impacting the market share of older drugs like lorazepam, although the established cost advantage of lorazepam is a strong counter-factor.

Despite the availability of newer pharmaceutical agents, lorazepam maintains a stable position in the market due to its established efficacy, broad availability, and low cost. The injectable formulation also retains importance in acute care settings, emergency departments, and for procedural sedation.

Price Projections

Price projections for ATIVAN (lorazepam) are primarily influenced by the dynamics of the generic pharmaceutical market. The brand-name ATIVAN pricing is largely dictated by manufacturer strategy, formulary agreements, and patient assistance programs. Generic lorazepam pricing, however, is driven by intense competition among multiple manufacturers.

Brand Name (ATIVAN): The list price for brand-name ATIVAN can vary significantly based on dosage, formulation, and pharmacy. For example, a 1 mg tablet of ATIVAN could have a cash price ranging from $10 to $30 per tablet. [4] However, actual out-of-pocket costs for insured patients are typically much lower, determined by co-pays and formulary tiers. The manufacturer's pricing strategy for ATIVAN is unlikely to see significant increases that deviate from established pharmaceutical pricing trends, as it competes with deeply discounted generics.

Generic Lorazepam: The price of generic lorazepam is highly competitive and subject to fluctuation based on supply, demand, and the pricing strategies of individual manufacturers.

• Current Pricing Landscape: A 1 mg tablet of generic lorazepam can typically be purchased for between $0.10 and $0.50 per tablet, depending on the manufacturer, quantity, and pharmacy. [4] For instance, a bottle of 30 tablets of 1 mg generic lorazepam might cost between $3 and $15.
• Factors Influencing Future Pricing:
  • Manufacturing Costs: Raw material costs, synthesis complexity, and regulatory compliance contribute to the baseline manufacturing cost. These are generally stable for established generics.
  • Competition: The presence of numerous generic manufacturers actively drives prices down. Any exit of a significant manufacturer could temporarily reduce supply and lead to minor price upticks, but new entrants or existing players typically fill any voids.
  • Supply Chain Disruptions: Global events impacting raw material sourcing or manufacturing capacity can lead to temporary price increases due to scarcity. However, lorazepam’s established manufacturing processes and multiple production sites globally mitigate this risk to some extent.
  • Regulatory Changes: FDA approvals for new generic manufacturers or stricter quality control measures could influence production costs and, consequently, pricing.
  • Demand Fluctuations: While overall demand for anxiolytics is growing, specific shifts in prescribing patterns or the introduction of highly effective alternative treatments could impact lorazepam demand and pricing.

Price Projections (2024-2029):

Generic Lorazepam: The price of generic lorazepam is projected to remain relatively stable with marginal declines over the next five years. Intense competition will continue to suppress significant price increases. Minor fluctuations may occur due to supply chain issues or changes in the number of active manufacturers.

• 2024-2025: Expect prices to remain within the current range ($0.10 - $0.50 per tablet for 1 mg).
• 2026-2029: A slight downward trend or continued stability is anticipated. Prices may settle towards the lower end of the current range ($0.10 - $0.40 per tablet for 1 mg) as manufacturers optimize production and compete aggressively on cost.

Brand Name ATIVAN: The pricing for brand-name ATIVAN will likely follow general pharmaceutical brand pricing trends, with modest annual increases. However, its market share will continue to be constrained by the availability of significantly cheaper generic alternatives.

• 2024-2029: Expect annual price increases in the range of 2-5%, reflecting industry norms for branded pharmaceuticals. This means a 1 mg tablet could see its cash price increase from approximately $15-$30 to $18-$37 by 2029, assuming a consistent increase.

The core driver for lorazepam's market position is its established efficacy and its ability to be produced at a very low cost, making it a foundational treatment in its class. The high volume of generic competition ensures this cost advantage will persist.

Key Takeaways

• Generic Dominance: The market for lorazepam is overwhelmingly dominated by generic manufacturers following the expiration of original patents decades ago.
• Price Competition: Intense competition among multiple generic suppliers keeps prices for generic lorazepam exceptionally low, typically ranging from $0.10 to $0.50 per 1 mg tablet.
• Stable Demand: The rising global prevalence of anxiety disorders and insomnia, coupled with lorazepam's efficacy and cost-effectiveness, ensures stable and potentially growing demand.
• Brand Name Strategy: Brand-name ATIVAN (Pfizer) maintains a niche presence but faces significant pricing pressure from generics. Its pricing will likely see modest annual increases.
• Price Projections: Generic lorazepam prices are projected to remain stable with a slight downward trend ($0.10-$0.40 per 1 mg tablet by 2029). Brand-name ATIVAN prices are expected to increase by 2-5% annually.
• Market Influencers: Key factors influencing the market include the number of generic manufacturers, manufacturing costs, supply chain stability, and the overall prevalence of anxiety and sleep disorders.

Frequently Asked Questions

1. Will new patents emerge for lorazepam that could impact generic competition? No. The fundamental composition and use patents for lorazepam have long expired. Any new patents would likely pertain to novel formulations, delivery methods, or combination therapies, which are unlikely to significantly alter the pricing landscape for standard oral or injectable lorazepam.

2. What is the primary driver of generic lorazepam price fluctuations? The primary driver is the dynamic interplay between the number of active generic manufacturers and their production capacity relative to market demand. Minor fluctuations can also occur due to supply chain disruptions for raw materials or intermediate compounds.

3. How does the pricing of lorazepam compare to newer anxiolytic drugs? Generic lorazepam is significantly more cost-effective. Newer anxiolytics, especially those still under patent protection or recently off-patent, are typically priced orders of magnitude higher per dose. For example, a month's supply of a branded SSRI or SNRI can cost $100-$200 or more, compared to a few dollars for generic lorazepam.

4. Are there any significant manufacturing or supply chain risks for generic lorazepam? While global supply chains can be vulnerable, lorazepam is a well-established drug with mature manufacturing processes and multiple global production sites. This broad manufacturing base reduces the risk of significant, long-term supply disruptions that could drastically impact pricing for the generic product.

5. Does the injectable formulation of lorazepam have different pricing dynamics than oral tablets? Injectable formulations generally carry a higher manufacturing cost due to sterility requirements and packaging complexities. Consequently, injectable lorazepam is priced higher per milligram than oral tablets, though it remains cost-effective compared to branded or newer injectable sedatives. The market for injectable lorazepam is also more concentrated, with fewer manufacturers compared to oral tablets.

---

Citations

[1] Food and Drug Administration. (1987). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Department of Health and Human Services. (Specific patent expiry dates are publicly available via the FDA's Orange Book database and historical patent records.)

[2] Market Research Report. (2023). Anxiolytics Market Size, Share & Trends Analysis Report By Drug Class, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Grand View Research.

[3] World Health Organization. (2022). Depression and other common mental disorders: strengthening the response. Retrieved from https://www.who.int/news-room/fact-sheets/detail/depression-and-other-common-mental-disorders-stronger-together

[4] Prescription Drug Price Comparison Websites. (Data accessed variously in 2023-2024). Information compiled from platforms such as GoodRx, SingleCare, and RxList, which aggregate pharmacy pricing data for brand and generic medications. (Note: Specific prices are estimates and can vary by pharmacy, location, insurance, and coupon usage.)